We evaluated the predictive power of age, creatinine, and ejection fraction (ACEF) score on mortality at 5-year follow-up in a population of 471 patients with chronic coronary syndrome (CCS) treated with percutaneous coronary intervention (PCI). Patients in the ACEF-High tertile showed the highest incidence of death at 5 years (15.7% vs. 2.6% in ACEF-Low and 4.3% in ACEF-Mid; log rank p<0.001). The ACEF score could significantly discriminate between patients who died and those who were still alive at 5 years (AUC 0.741, 95% CI 0.654-0.828), and an ACEF score >1.32 was identified as the optimal cutoff point to predict 5-year mortality (sensitivity 74%, specificity 68%). An ACEF score >1.32 was an independent predictor of 5-year mortality (HR 5.77, 95% CI 2.70-12.31; p<0.001). Our study shows that the ACEF score can predict mortality at 5-year follow-up in patients with CCS treated with PCI.

我们评估了年龄、肌酐和射血分数 (ACEF) 评分对 471 名接受经皮冠状动脉介入治疗 (PCI) 治疗的慢性冠状动脉综合征 (CCS) 患者的 5 年随访死亡率的预测能力。ACEF-High 三分位数的患者在 5 年时的死亡率最高（ACEF-Low 为 15.7%，ACEF-Low 为 2.6%，ACEF-Mid 为 4.3%；对数秩p <0.001）。ACEF 评分可以显着区分死亡患者和 5 年仍存活患者（AUC 0.741，95% CI 0.654-0.828），ACEF 评分>1.32 被确定为预测 5 年死亡率的最佳截止点（敏感性 74%，特异性 68%）。ACEF 评分 >1.32 是 5 年死亡率的独立预测因子（HR 5.77，95% CI 2.70-12.31；p<0.001)。我们的研究表明，ACEF 评分可以预测接受 PCI 治疗的 CCS 患者 5 年随访时的死亡率。